Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetophenone SCHEMBL28186726 | 0.85 | CYP1A2 (0.58) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 | |
| 4-Hydroxyacetophenone SCHEMBL11444527 | 0.82 | MAPT (0.56) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 | |
| SCHEMBL6906973 | 0.80 | RAB9A (0.60) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 | |
| SCHEMBL29043036 | 0.80 | MAPT (0.57) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 | |
| SCHEMBL4853473 | 0.80 | MAPK13 (0.52) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL50646 | 0.79 | MAPT (0.68) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 | |
| SCHEMBL24206451 | 0.78 | MAPT (0.44) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL7034 | 0.78 | TSHR (0.60) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL11353187 | 0.78 | ALDH1A1 (0.52) | MAPTSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL912761 | 0.78 | KMT2A (0.56) | MAPTRAB9ANPC1SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268038-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS | AGENSYS INC (US) | 2021-05-05 | — | — | EP | claimed |
| CN-112574077-B | Method for synthesizing sulfone compound under photocatalysis condition | 河南大学 | 2022-02-22 | — | — | CN | disclosed |
| US-11147815-B2 | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses | SYNKRINO BIOTHERAPEUTICS, INC. | 2021-10-19 | — | — | US | disclosed |
| CN-112574077-A | Method for synthesizing sulfone compound under photocatalysis condition | 河南大学 | 2021-03-30 | — | — | CN | disclosed |
| EP-2797417-B1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2019-07-31 | — | — | EP | disclosed |
| CN-105801544-A | 3-aryl-4-arylamine-coumarin derivative and preparing method and medical application thereof | 中国药科大学 | 2016-07-27 | — | — | CN | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-8729228-B2 | Method of producing a modified (poly) peptide | UNIVERSITY OF GENEVA (CH) | 2014-05-20 | — | — | US | disclosed |
| EP-1979371-B1 | METHOD OF PRODUCING A MODIFIED (POLY)PEPTIDE | UNIV GENEVE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20070048217-A1 | F-18 peptides for pre targeted positron emission tomography imaging | IMMUNOMEDICS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070026535-A1 | Novel methodology of conjugating chelators to biomolecules | KPL, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-6534041-B1 | Having little or no fluorescence emission until dye is cleaved from construct at tumor or inflammation target site | INSTITUTE FOR DIAGNOSTIC RESEARCH GMBH OF THE FREE UNIVERSITY OF BERLIN (DE) | 2003-03-18 | — | — | US | disclosed |
| US-20010044553-A1 | Novel compound for color-producing composition, and recording material | CHEMIPRO KASEI KAISHA, LTD. (JP) | 2001-11-22 | — | — | US | disclosed |
| CN-1253507-A | Acid-labile and enzymatically divisible dye structure for diagnosis with near infrared light and for therapy | DIAGNOSTIKFORSCHUNG INST (DE) | 2000-05-17 | — | — | CN | disclosed |
| EP-0988060-A2 | ACID-LABILE AND ENZYMATICALLY DIVISIBLE DYE COMPOUNDS FOR DIAGNOSIS WITH NEAR INFRARED LIGHT AND FOR THERAPY | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998047538-A2 | ACID-LABILE AND ENZYMATICALLY DIVISIBLE DYE COMPOUNDS FOR DIAGNOSIS WITH NEAR INFRARED LIGHT AND FOR THERAPY | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1998-10-29 | — | — | WO | disclosed |
| US-5106814-A | Containing aromatic isocyanate, imino compound, trialkoxy benzoate; image stability, responsiveness | MITSUBISHI PAPER MILLS LIMITED (JP) | 1992-04-21 | — | — | US | disclosed |
| US-4448961-A | Substituted anilino pyrimidines | ZOECON CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| US-4411839-A | α-Cyano-β-(trisubstituted phenylhydrazino)-n-ethoxycarbonylacrylamides | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SPR, QDPR, SRR | MAPT 2193/4885RAB9A 3428/4885NPC1 2778/4885 |
| US-20070048217-A1 | F-18 peptides for pre targeted positron emission tomography imaging | SSTR4, NPPA, ANPEP | MAPT 2678/4885RAB9A 977/4885NPC1 1363/4885 |
| US-11147815-B2 | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses | TRIM28, TRIM58, CD14 | MAPT 1064/4885RAB9A 2830/4885NPC1 2530/4885 |
| US-20070026535-A1 | Novel methodology of conjugating chelators to biomolecules | SLC40A1, SLC30A6, CACYBP | MAPT 3496/4885RAB9A 2392/4885NPC1 1574/4885 |
| US-20010044553-A1 | Novel compound for color-producing composition, and recording material | UROD, UMPS, UGT1A10 | MAPT 979/4885RAB9A 1884/4885NPC1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.